-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Aneurysmal subarachnoid hemorrhage (SAH) is associated with significant morbidity and mortality
Aneurysmal subarachnoid hemorrhage (SAH) The optimal duration of treatment after the onset of aneurysmal SAH is unclear, and definitions of early and delayed treatment vary widely
Therefore, strong evidence on the optimal timing of surgery is still lacking
The study included 575 retrospectively identified first cases of aneurysmal SAH reported between January 2010 and December 2016 in a referral network of two major tertiary hospitals in Australia
It found a non-linear association between treatment delay and the likelihood of being discharged home and recovery
Nonlinear association between treatment delay and likelihood of being discharged home and recovery Sex, treatment modality, severity, Charlson comorbidity index, history of hypertension and hospital transfer Sex, treatment modality, severity, Charlson comorbidity index, high Blood pressure history and hospital transfers
This cohort study suggests that treatment of aneurysmal SAH is best done within 12.
Treatment of aneurysmal SAH is best done within 12.
Original source:
Buscot MJ, et al.
Association of Onset-to-Treatment Time With Discharge Destination, Mortality, and Complications Among Patients With Aneurysmal Subarachnoid Hemorrhage
leave a message here